Medical Information & Treatment Mandatories

At Auré Aesthetics, all injectable and medical aesthetic treatments are provided following an individual clinical assessment and informed consent process. Treatments are performed by appropriately qualified healthcare professionals within their scope of practice and in accordance with applicable New Zealand requirements, product information and clinical protocols. All treatments have potential risks and benefits. Your practitioner will discuss the suitability of treatment, expected results, alternatives, potential complications and aftercare with you before treatment.

Dysport® is a prescription medicine for the treatment of frown lines, horizontal forehead lines and crow's feet around the eyes. Dysport® has risks and benefits. Ask your doctor if Dysport is right for you. If you have side effects see your doctor. You will need to pay for Dysport, and clinic fees will apply. For details on precautions & side effects consult your healthcare professional or the Consumer Medicine Information (CMI) at www.medsafe.govt.nz. Dysport lasts about 4-6 months and further courses of treatment may be necessary. Should only be administered by trained medical professionals. Contains 500 units of clostridium botulinum Type A toxin. Galderma (NZ) Limited, Auckland.

Xeomin® is a Prescription Medicine containing 50, 100 units of incobotulinum Type A, purified Botulinum toxin type A complex for injection. It is used for the treatment of frown lines on the forehead, lateral periorbital lines and horizontal forehead lines in adults. It should be administered only by trained medical professionals. Talk to your specialist about the benefits/risks of this procedure in appearance medicine. Xeomin® treatment lasts about four months and further courses of treatment may be necessary. Cautions: people receiving blood thinning medicines, care at the proposed injection sites, pregnancy and lactation. Possible side effects: headache, pain, swelling or infection at injection site, local muscle weakness including drooping eye lids, lack of feeling & nausea. Treatment last for up to 4 months. You will need to pay for this medicine. Discuss with your specialist if Xeomin® is right for you. For more information or for a copy of CMI please contact the NZ distributor: Merz, Sydney. Distributed by Healthcare Logistics, Auckland.

Profhilo®, containing low & high molecular weight hyaluronic acid, is a Class III medical device for the treatment of the face and body for contours redefinition and laxity remodelling where skin laxity is a problem. Profhilo® has risks and benefits. Do not use with treatments such a laser resurfacing or medium deep skin-peeling. Caution in people on blood thinning medicines. Do not inject into inflamed areas or intravenously or intramuscularly. Possible side effects: pain and swelling at injection site. Please refer to instructions for use, local distributor. Healthcare Logistics, Auckland.

REJURAN® is a Class Ill Medical Device designed for tissue restoration, reconstruction, and improvement of physical appearance. REJURAN® has both risks and benefits. Consult your medical practitioner to determine if REJURAN® Injectables are right for you. Each injection contains 20mg/ml of stabilised polynucleotides (PN). For product information, refer to your medical practitioner or the supplier's product details. Always follow your medical practitioner's instructions. This medical device must be administered by a trained professional. Unfunded in NZ. Product and treatment costs apply. For further information, including precautions and contraindications, visit www.rejuran.co.nz or contact the distributor, K Bridge Medical Pty Lta, Australia, via email at info@koridge.com.au. Always read the label and follow directions for use. This product is not available for purchase by the general public. MR11537.

Radiesse® injectable implant is intended for plastic and reconstructive surgery, including deep dermal and sub-dermal soft tissue augmentation of the facial area and dorsum of the hands. Radiesse® injectable implant is indicated for: the treatment of nasolabial folds, marionette lines or jawline; the augmentation of cheeks; the hand augmentation to correct volume loss in the dorsum of the hands; and the restoration and/or correction of the signs of facial fat loss (lipoatrophy) in people with human immunodeficiency virus. Radiesse® (+) Lidocaine injectable implant is intended for plastic and reconstructive surgery, including deep dermal and sub-dermal soft tissue augmentation of the facial area and dorsum of the hands in adults. Radiesse® (+) Lidocaine injectable implant is indicated for: the treatment of nasolabial folds, marionette lines and jawline; the augmentation of cheeks; hand augmentation to correct volume loss in the dorsum of the hands; the restoration and/or correction of the signs of fat or volume loss (lipoatrophy) in the facial area and for rejuvenation of the hands fat loss (lipoatrophy) in people with human immunodeficiency virus. You should tell your practitioner and avoid treatment with Radiesse®/Radiesse® (+) Lidocaine if you: have had an allergic reaction to any of the ingredients or have severe allergies including anaphylaxis; if you tend to develop keloids or heavy scars; have any bleeding disorders, poor wound healing; inflamed or infected skin; are under the age of 18; are pregnant or breastfeeding. Please inform your practitioner of any diseases you have or have had. These include in particular cardiovascular diseases, autoimmune diseases, diabetes, tumors, skin infections or severe allergies. If you take medication or vitamins, have had previous cosmetic procedures, or have been treated with other implants, please inform your practitioner. Always read the label and consult your Healthcare Professional for more information. This medical device must be administered by a Healthcare Professional. Merz Australia Pty Ltd (ACN: 151 073 559) Sydney, Australia. NZ Distribution: Pharmacy Retailing NZ Limited t/a Health Care Logistics (HCL). 58 Richard Pearse Drive, Mangere, Auckland 2022. For more information please phone 0800 822 310.

Restylane® is a natural cosmetic dermal filler that restores volume and fullness to the skin to smooth facial wrinkles and folds, enhance facial shape or to create fuller lips. Restylane® is available through prescription only from a medical professional, and is delivered by injection into or below the skin. It is not to be injected into blood vessels as this may lead to a lack of blood supply to the skin and ulceration and scarring. Restylane® contains hyaluronic acid, naturally found in the human body and is thought to help increase moisture in the skin. Treatment benefits are instant, do not affect facial expression and results usually last 6-12 months. Ongoing treatments are needed to maintain best results. After a Restylane® treatment you may expect some degree of redness, swelling, pain or tenderness, itching and/or bruising which generally only lasts a few days. Inflammatory reactions may last up to two weeks in rare cases. Adverse effects from treatment are extremely rare and may include allergy, infection, granuloma formation, persistent discoloration at the injection site, and/or ulceration of the skin. Exposure to sunlight should be avoided during the initial post treatment phase. Restylane® should not be used in or near sites where there are active skin disease, inflammation or infection, or where a permanent implant has been placed. Restylane® is not recommended for people taking blood thinning medicines or Roaccutane for acne, and has not been tested in pregnant or breast-feeding women. Restylane® is an unfunded Prescription medicine, and there will be a charge for the medicine and consultation. Ask you specialist if Restylane is right for you. Contains: Hyaluronic acid 20mg/ml phosphate buffered saline, pH 7 q.s. Q-Med Ltd, Auckland. Distributed by Healthcare Logistics, Auckland.

Belotero® Medical Device Class III to smooth facial wrinkles and folds, correct facial atrophic scars, restore or enhance the lips or restore facial volume. Belotero has risk and benefits. Ask your doctor if Belotero is right for you. For product information check with your doctor or from product details with the supplier. Click for further details. Contains Sodium Hyaluronate Gel. Merz, Sydney. Distributed by Healthcare Logistics, Auckland.

Aqualyx® is an injectable Class III medical device based on the deoxycholate family of acids. It is designed for targeted reduction of localised subcutaneous fat and body contouring rather than general weight loss. The current New Zealand Aqualyx information states that the product is Medsafe registered and available through certified clinics. Aqualyx® has risks and benefits. It is not a treatment for obesity or a substitute for weight management. Treatment may be considered for selected areas of localised fat, including the submental area (double chin) and other suitable body areas following clinical assessment. Possible side effects include pain, tenderness, swelling, bruising, redness, warmth, itching, numbness and temporary firmness or lumps in the treated area. More significant inflammatory reactions, infection, tissue injury, nerve injury or other complications may occur. Aqualyx® is not suitable for everyone. Treatment may be unsuitable during pregnancy or breastfeeding, in the presence of active infection or inflammation at the treatment site, or in people with certain medical conditions, coagulation disorders or sensitivities to the product components. Your practitioner will assess the treatment area, skin quality, medical history and suitability before treatment. Aqualyx® treatment is intended for targeted contouring. Results vary between individuals and multiple treatments may be required. Only genuine, traceable Aqualyx® supplied through the authorised New Zealand distribution pathway should be used.

Juvelook® is an injectable aesthetic product used in skin-rejuvenation treatments. The specific formulation, intended use, regulatory classification and Instructions for Use depend on the exact Juvelook® product supplied. Juvelook® has risks and benefits. Treatment involves multiple injections and may result in temporary swelling, redness, bruising, tenderness, itching or small raised areas at injection sites. Possible complications of injectable treatments include infection, inflammatory reactions, nodules, asymmetry, pigment changes and other local or systemic reactions. Treatment should not be performed through active infection, significant inflammation or compromised skin. Your practitioner will assess your suitability based on your medical history, medications, allergies, previous injectable treatments and treatment goals. Important: Product-specific indications, contraindications, preparation and administration requirements must be followed according to the current manufacturer Instructions for Use for the exact Juvelook® product used.

All injectable treatments carry inherent risks, including bleeding, bruising, infection, inflammation, allergic reactions, nerve or tissue injury and other complications. Some injectable treatments carry rare but potentially serious complications, including vascular compromise and tissue injury. If you experience severe or worsening pain, significant or unusual swelling, marked skin discolouration, blistering, visual disturbance, difficulty swallowing or breathing, facial weakness, or any other concerning symptoms following treatment, seek urgent medical assessment. Your practitioner will provide individualised aftercare instructions and advise you when to contact the clinic or seek urgent medical attention. Treatment outcomes cannot be guaranteed. Results vary between individuals and may be affected by age, anatomy, skin condition, lifestyle, medications, previous treatments and individual response. All treatments are subject to clinical assessment and may be declined where treatment is considered unsuitable or unsafe. For prescription medicines, patients may request the applicable Consumer Medicine Information (CMI) and Data Sheet. Current New Zealand medicine information is available through Medsafe's Data Sheet and CMI database. Medsafe: www.medsafe.govt.nz